• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association of beta-blocker therapy at discharge with clinical outcomes in patients without heart failure or left ventricular systolic dysfunction after acute coronary syndrome: An updated systematic review and meta-analysis
CONCLUSIONS: In patients without heart failure or left ventricular systolic dysfunction after ACS in the contemporary PCI era, beta-blocker therapy may still be beneficial due to a potential reduced risk of all-cause death.PMID:36376209 | DOI:10.1016/j.acvd.2022.09.004
Source: Archives of Cardiovascular Diseases - November 14, 2022 Category: Cardiology Authors: Meng-Jin Hu Xiao-Ning Wang Jiang-Shan Tan Yue-Jin Yang Source Type: research

Implications of Under-Reporting Medication Side Effects: Beta-Blockers in Heart Failure as a Case Example
ConclusionWe conclude that under-reporting perceived side effects of beta-blockers among adults with heart failure is common, is associated with Black race and low education, and may contribute to patient willingness to take additional medication to prevent future medical encounters.
Source: Drugs and Aging - February 17, 2023 Category: Geriatrics Source Type: research

Development and validation of dynamic models to predict postdischarge mortality risk in patients with acute myocardial infarction: results from China Acute Myocardial Infarction Registry
Conclusions We established dynamic risk prediction models incorporating adverse event and medications. The nomograms may be useful instruments to help prospective risk assessment and management of AMI. Trial registration number NCT01874691.
Source: BMJ Open - March 29, 2023 Category: General Medicine Authors: Lv, J., Wang, C., Gao, X., Yang, J., Zhang, X., Ye, Y., Dong, Q., Fu, R., Sun, H., Yan, X., Zhao, Y., Wang, Y., Xu, H., Yang, Y., on behalf of the China Acute Myocardial Infarction Registry study group Tags: Open access, Cardiovascular medicine Source Type: research

Clinical Efficacy and Safety of Early Intravenous Administration of Beta-Blockers in Patients Suffering from Acute ST-Segment Elevation Myocardial Infarction Without Heart Failure Undergoing Primary Percutaneous Coronary Intervention: A Study-Level Meta-Analysis of Randomized Clinical Trials
ConclusionIntravenous beta-blockers improved the MSI, decreased the risk of VT/VF in the first 24 h, and were associated with increased LVEF at 1 week and 6 months following PCI. In particular, intravenous beta-blockers started before PCI is beneficial for patients with LAD lesions.
Source: Cardiovascular Drugs and Therapy - April 1, 2023 Category: Cardiology Source Type: research

Atrial fibrillation, cancer and anticancer drugs
Arch Cardiovasc Dis. 2023 Mar 11:S1875-2136(23)00058-X. doi: 10.1016/j.acvd.2023.02.005. Online ahead of print.ABSTRACTActive cancer is associated with an increased risk of atrial fibrillation (AF), which varies depending on the pre-existing substrate (particularly in older patients), the cancer type and stage, and the anticancer therapeutics being taken. To date, studies have not been able to identify the individual contribution of each factor. During anticancer drug therapy, AF may occur with a frequency of ≈ 15-20% according to several factors, including the patient's baseline cardiovascular toxicity risk and the AF-d...
Source: Archives of Cardiovascular Diseases - March 31, 2023 Category: Cardiology Authors: Jonaz Font Paul Milliez Alexandre-Boudjema Ouazar Frederikus A Klok Joachim Alexandre Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13